✨ Health Notices




4 APRIL 2013 NEW ZEALAND GAZETTE, No. 39 1187

Product: Nupentin
Active Ingredient: Gabapentin 300mg
Dosage Form: Capsule
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Alphapharm Pty Limited, Brisbane, Australia

Product: Nupentin
Active Ingredient: Gabapentin 400mg
Dosage Form: Capsule
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Alphapharm Pty Limited, Brisbane, Australia

Product: Simponi
Active Ingredient: Golimumab 50mg
Dosage Form: Solution for injection
New Zealand Sponsor: Janssen-Cilag (New Zealand) Limited
Manufacturer: Baxter Pharmaceutical Solutions LLC, Indiana, United States of America

Product: Simponi SmartJect Injector
Active Ingredient: Golimumab 50mg
Dosage Form: Solution for injection
New Zealand Sponsor: Janssen-Cilag (New Zealand) Limited
Manufacturer: Baxter Pharmaceutical Solutions LLC, Indiana, United States of America

Dated this 28th day of March 2013.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go1973

Misuse of Drugs Act 1975

Temporary Class Drug Notice

Pursuant to section 4E of the Misuse of Drugs Act 1975, I give notice that the following substances are renewed as temporary class drugs:

AM-1248
1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole

AM-2232
5-(3-(1-naphthoyl)-1H-indol-1-yl)pentanenitrile

UR-144
(1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone

This notice will take effect on 7 April 2013 and will expire on 6 April 2014, unless otherwise revoked as specified in section 4E of the Misuse of Drugs Act 1975.

Dated at Wellington this 28th day of March 2013.

HON PETER DUNNE, Associate Minister of Health.

go1985

Temporary Class Drug Notice

Pursuant to section 4E of the Misuse of Drugs Act 1975, I give notice that the following substance is renewed as a temporary class drug:

DMAA
1,3-dimethylamylamine or 4-methylhexane-2-amine

This notice will take effect on 10 April 2013 and will expire on 9 April 2014, unless otherwise revoked as specified in section 4E of the Misuse of Drugs Act 1975.

Dated at Wellington this 28th day of March 2013.

HON PETER DUNNE, Associate Minister of Health.

go1986



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2013, No 39





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines - Nupentin and Simponi (continued from previous page)

πŸ₯ Health & Social Welfare
28 March 2013
Medicines Act, New Medicines, Distribution Consent, Nupentin, Simponi, Gabapentin, Golimumab
  • Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health

πŸ₯ Temporary Class Drug Notice - AM-1248, AM-2232, UR-144

πŸ₯ Health & Social Welfare
28 March 2013
Misuse of Drugs Act, Temporary Class Drugs, AM-1248, AM-2232, UR-144
  • Hon Peter Dunne, Associate Minister of Health

πŸ₯ Temporary Class Drug Notice - DMAA

πŸ₯ Health & Social Welfare
28 March 2013
Misuse of Drugs Act, Temporary Class Drugs, DMAA
  • Hon Peter Dunne, Associate Minister of Health